iTeos Therapeutics, Inc. (NASDAQ:ITOS) reported topline results from an updated interim analysis of the GALAXIES Lung-201 Phase 2 study on Tuesday. The trial sponsored by GSK Plc (NYSE:GSK) assessed ...
Concentra has offered to buy iTeos for $10.05 per share in cash—just below the $10.26 that the biotech’s stock closed at on Friday. (flytosky11/iStock/Getty ...
Just two weeks after dropping a TIGIT candidate jointly developed with GSK, iTeos has announced plans to wind down operations and explore strategic alternatives. The first half of this year has been ...
Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: Company logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility (Reuters) -Britain's ...
LVS Advisory, a New York City-based full-service investment firm, recently released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first half of 2025, the ...
TIGITs took another tumble with GSK plc’s decision to end a development program and a collaboration with Iteos Therapeutics Inc. New top-line results from a phase II study in non-small-cell lung ...
WATERTOWN, Mass. and GOSSELIES, Belgium, May 13, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development ...
GlaxoSmithKline is boosting its cancer drug pipeline through a partnership with iTeos Therapeutics, a deal that gives the pharmaceutical giant a chance to catch up to its peers in the pursuit of a hot ...
CAMBRIDGE, Mass. and GOSSELIES, Belgium, Nov. 12, 2020 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development ...
- Began enrolling patients with head and neck squamous cell carcinoma in Phase 2 trial expansion evaluating anti-TIGIT monoclonal antibody, EOS-448/GSK4428859A, and GSK’s anti-PD-1 Jemperli ...
Our round-up of notable biotech financings in the last week includes a $120 million direct offering for immunology and inflammation biotech iTeos, and private rounds for Lycia, Attovia, Ajax, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results